A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease.

Trial Profile

A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Eltoprazine (Primary)
  • Indications Dyskinesias; Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors PsychoGenics
  • Most Recent Events

    • 17 Apr 2017 Results published in an Amarantus Bioscience Holdings media release.
    • 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 15 Jun 2015 According to Amarantus Biosciences Holdings media release, data from this phase I/IIA study was poster presented at the 19th International Congress of Parkinson's Disease and Movement Disorders 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top